Our Partners_ViraTherapeutics Our Partners_ViraTherapeutics Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
Research-collaboration-Gubra-obesity-treatment Research-collaboration-Gubra-obesity-treatment Boehringer Ingelheim and Gubra enter collaboration to identify and validate targets and innovative peptides for the treatment of obesity.
The digital therapeutic solution halving hospitalization rates The digital therapeutic solution halving hospitalization rates Around 750,000 people live with chronic heart failure in Canada. The Medly program empowers patients with heart failure to manage their condition
Vetmedin® Vetmedin® Treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid regurgitation).
Boehringer Ingelheim 2022 half year results Boehringer Ingelheim 2022 half year results First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Immunology Respiratory Research Immunology Respiratory Research Find out more about our research and development in Immunology & Respiratory diseases
Thelaziosis dog eyeworms Thelaziosis dog eyeworms Have you heard of Thelaziosis? In Europe, some fruit flies host an emerging parasite known as “eyeworm”, an infestation which causes more or less severe conjunctivitis, sometimes leading to corneal ulcers and even blindness in dogs.
Taking cancer on together Taking cancer on together Through their work, our colleagues from around the world hope to empower patients to Take Cancer On.
Disentangling fibrosis Disentangling fibrosis Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
Our Venture Fund on the search for groundbreaking trends Our Venture Fund on the search for groundbreaking trends The Boehringer Ingelheim Venture Fund acquires minority stakes in biotech start-ups, and even supports the majority before and during their founding.
Celebrating 20 years of Metacam for cattle Celebrating 20 years of Metacam for cattle Celebrating 20 years of Metacam (Meloxicam) for cattle
collaboration-LIBD collaboration-LIBD Boehringer Ingelheim and The Lieber Institute for Brain Development collaborate on centrally acting COMT inhibitors in neuropsychiatric disorders
Immunology Immunology We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in immunology.
Phase 1 start of treatment for Geographic Atrophy patients Phase 1 start of treatment for Geographic Atrophy patients Boehringer initiates Phase 1 evaluation of BI 771716 a treatment for preserving vision of people living with geographic atrophy (GA)